Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients—A Multiparametric Prediction
Authors:
- Sergio Muñoz-MartínezSMSergio Muñoz-Martínez
- Victor SapenaVSVictor Sapena
- Ángeles García-CriadoÁGÁngeles García-Criado
- Anna DarnellADAnna Darnell
- Alejandro FornerAFAlejandro Forner
- Ernest BelmonteEBErnest Belmonte
- Marco Sanduzzi-ZamparelliMSMarco Sanduzzi-Zamparelli
- Jordi RimolaJRJordi Rimola
- Alexandre SolerASAlexandre Soler
- Neus LlarchNLNeus Llarch
- Gemma IserteGIGemma Iserte
- Ezequiel MauroEMEzequiel Mauro
Open Access
Abstract
Background: Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients’ outcomes after recurrence. The present study evaluates the impact of patient and tumor characteristics at baseline and at recurrence on the Clinical Decision-Making process. Methods: We evaluated BCLC-0/A patients treated with percutaneous ablation from January 2010 to November 2018. Clinical and radiological data such as age, tumor location at ablation, pattern of recurrence/progression, and comorbidities during follow-up were registered. Tumor location was divided into ‘suboptimal’ vs. ‘optimal’ locations for ablation. The Clinical Decision-Making was based on tumor burden, liver dysfunction, or comorbidities. The statistical analysis included the time-to-recurrence/progression, censoring at time of death, date of last follow-up or liver transplantation, and time-to-event was estimated by the Kaplan–Meier method and Cox regression models to evaluate the risk of an event of death and change of treatment strategy. Results: A total of 225 patients [39.1% BCLC-0 and 60.9% BCLC-A] were included, 190 had unifocal HCC and 82.6% were ≤3 cm. The complete response rate and median overall survival were 96% and 60.7 months. The HCC nodules number (Hazard Ratio—HR 3.1), Child-Pugh (HR 2.4), and Albumin-Bilirubin score (HR 3.2) were associated with increased risk of death during follow-up. HCC in ‘suboptimal location’ presented a shorter time to recurrence. When comorbidities prevented further loco-regional or systemic treatment, the risk of death was significantly increased (HR 2.0, p = 0.0369) in comparison to those who received treatment. Conclusions: These results expose the impact of non-liver comorbidities when considering treatment for recurrence after ablation in the real-world setting and in research trials. Ultimately, we identified an orphan population for which effective interventions are needed.Keywords
This publication has 43 references indexed in Scilit:
- Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological ResponsePLOS ONE, 2013
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Radiofrequency ablation of hepatocellular carcinoma: Long-term results and prognostic factors in 235 Western patients with cirrhosis #Hepatology, 2009
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- Recurrence-free Survival after Radiofrequency Ablation of Hepatocellular Carcinoma. A Registry Report of the Impact of Risk Factors on OutcomeJapanese Journal of Clinical Oncology, 2007
- AASLD practice guidelinesHepatology, 2005
- Initial Response To Percutaneous Ablation Predicts Survival in Patients With Hepatocellular CarcinomaHepatology, 2004
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablationJournal of Gastroenterology, 2003
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001